Eicosadienoic Acid
Background
Eicosadienoic acid is a polyunsaturated fatty acid (PUFA) characterized by a 20-carbon chain and two double bonds (20:2). As a lipid molecule, it is an integral part of the complex network of fatty acid metabolism within the human body.
Biological Basis
Fatty acids like eicosadienoic acid are crucial components of cell membranes and precursors for various signaling molecules. Their biosynthesis and interconversion are regulated by specific enzymes, most notably those encoded by the fatty acid desaturase (FADS) gene cluster, which includes FADS1, FADS2, and FADS3. [1] These desaturase enzymes are responsible for introducing double bonds into fatty acid chains, a critical step in producing longer-chain polyunsaturated fatty acids from essential dietary fatty acids. [2] Genetic variations within the FADS gene cluster have been associated with the composition of fatty acids in phospholipids, influencing the levels of various polyunsaturated fatty acids. [3]
Clinical Relevance
Variations in fatty acid profiles, including those related to eicosadienoic acid metabolism, are increasingly recognized for their connections to human health. Genome-wide association studies (GWAS) have identified common genetic variants within the FADS gene cluster that are associated with levels of polyunsaturated fatty acids in the blood. [3] These genetic influences on fatty acid composition can be relevant to overall lipid metabolism and, consequently, to conditions such as dyslipidemia and cardiovascular disease. [4] For instance, SNPs in the FADS gene cluster have been associated with both high-density lipoprotein (HDL) cholesterol and triglyceride levels. [1]
Social Importance
Understanding the genetic and metabolic factors influencing fatty acid levels, such as eicosadienoic acid, is important for public health. Insights gained from studies linking genetic variants to specific fatty acid profiles can contribute to personalized nutrition strategies and the development of targeted interventions for metabolic disorders. Given the widespread role of polyunsaturated fatty acids in various physiological processes and their association with cardiovascular health, research into eicosadienoic acid and its genetic determinants helps to elucidate pathways that could be amenable to lifestyle or pharmacological modulation.
Limitations
Research into complex traits, including eicosadienoic acid, faces several inherent limitations that shape the interpretation and generalizability of findings. These limitations span study design, measurement accuracy, and the comprehensive understanding of genetic and environmental influences. Acknowledging these constraints is crucial for contextualizing current knowledge and guiding future research directions.
Methodological and Statistical Constraints
The studies on eicosadienoic acid faced several methodological and statistical limitations that impact the interpretation of findings. Many investigations, particularly early genome-wide association studies (GWAS), were conducted with moderate sample sizes, which inherently limited statistical power to detect genetic effects of modest size, especially after accounting for extensive multiple testing. [5] This constraint means that some true genetic associations, particularly those explaining less than 4% of phenotypic variation or requiring a stringent significance threshold like 10^-8, may have been missed or underestimated, contributing to potential false negatives or an inflation of reported effect sizes for those signals that did reach significance. [5] Furthermore, some observed moderately strong associations might represent false-positive results, even if the associated single nucleotide polymorphisms (SNPs) appear biologically plausible. [5]
Another significant limitation stems from the incomplete coverage of genetic variation by the SNP arrays used, such as 100K SNP chips, which represent only a subset of all genetic variants in the HapMap project. [6] This partial coverage means that certain genes or causal variants might have been entirely missed due to a lack of directly genotyped SNPs in linkage disequilibrium with them, limiting the comprehensive study of candidate genes and the discovery of novel loci. [6] While imputation methods were employed to infer missing genotypes and facilitate comparisons across studies that used different marker sets, these methods rely on reference panels (e.g., HapMap CEU samples) and introduce an estimated error rate ranging from 1.46% to 2.14% per allele, potentially leading to imprecise estimations of SNP associations or an inability to accurately identify proxy SNPs. [7] Additionally, the adoption of an additive model of inheritance in many analyses might not fully capture complex genetic architectures, and a liberal genotyping call rate threshold (e.g., 80%) chosen for inclusivity could potentially introduce more noise into the association analyses. [1]
Phenotypic Measurement and Generalizability
Challenges related to phenotype measurement and the generalizability of findings also present critical limitations. Several studies involved averaging phenotypic traits across multiple examinations spanning up to twenty years and utilizing different equipment. [5] While intended to reduce regression dilution bias, this approach may introduce misclassification and masks age-dependent gene effects, as it assumes that the same genetic and environmental factors influence traits uniformly over a wide age range, which may not be accurate. [5] Moreover, to manage the multiple testing burden, some analyses were performed only as sex-pooled, meaning that specific genetic associations influencing phenotypes exclusively in males or females might have been overlooked. [6]
A major concern for the broader applicability of the research is that many studies were conducted predominantly in populations of European descent. [5] While efforts were made to control for population stratification within these groups using methods like genomic control and principal component analysis, the generalizability of the findings to other ethnic groups and ancestries remains largely unknown. [5] The reliance on HapMap CEU samples for imputation and proxy SNP identification further underscores this limitation, as correlations estimated in one ancestral group may not accurately reflect patterns in others. [8] Consequently, genetic variants identified in these studies might not have the same effect sizes or even be polymorphic in non-European populations, necessitating further research in diverse cohorts to confirm and expand upon these findings.
Unaccounted Genetic and Environmental Influences
Despite significant discoveries, a substantial portion of the heritability for complex traits like eicosadienoic acid levels remains unexplained, with associated loci often accounting for only a small percentage (e.g., 6%) of the total phenotypic variability. [8] This "missing heritability" highlights the existence of numerous unidentified genetic factors, including rare variants, structural variations, or complex epistatic interactions not captured by current GWAS designs. Furthermore, the causal variants underlying many identified associations frequently remain elusive, with reported SNPs often serving as markers for broader genomic regions that may harbor multiple genes with allelic heterogeneity. [8]
A critical gap in understanding is the limited investigation into gene-environment interactions. Genetic variants are known to influence phenotypes in a context-specific manner, with environmental factors potentially modulating their effects. [5] For instance, the impact of genes like ACE and AGTR2 on certain cardiovascular traits has been shown to vary with dietary salt intake. [5] The absence of comprehensive analyses exploring such interactions in the present studies means that the full spectrum of genetic influences on eicosadienoic acid, as well as potential population heterogeneity of effects, may not be fully appreciated. [5] This omission limits the ability to develop personalized prevention or treatment strategies that consider both an individual's genetic predisposition and their environmental exposures.
Variants
The genetic variant rs7160151 is located in a genomic region containing the pseudogenes RPL18P1 and ATP5MC2P2. Pseudogenes are non-coding DNA sequences that resemble functional genes but typically lack the ability to produce functional proteins themselves. Despite their non-coding nature, the genomic regions harboring pseudogenes can sometimes influence the expression or regulation of nearby or distant functional genes, potentially impacting complex traits like metabolic profiles. [9] Understanding the precise role of rs7160151 involves considering how its presence might affect cellular processes and metabolic pathways, including those related to fatty acid metabolism.
RPL18P1 is a pseudogene related to RPL18, which encodes a ribosomal protein. Ribosomal proteins are fundamental components of ribosomes, the cellular machinery responsible for protein synthesis. As protein synthesis is a core cellular process, variations in its efficiency or regulation can have widespread metabolic consequences, indirectly affecting the production of enzymes and transporters critical for lipid metabolism. [10] While RPL18P1 itself does not produce a functional ribosomal protein, its genomic context may harbor regulatory elements or exert epigenetic influences that contribute to the overall cellular metabolic state, potentially influencing the levels of various fatty acids, including eicosadienoic acid.
Similarly, ATP5MC2P2 is a pseudogene related to ATP5MC2 (also known as ATP5F1A or ATP5A1), a gene encoding a subunit of ATP synthase. ATP synthase is a crucial enzyme in mitochondria responsible for generating adenosine triphosphate (ATP), the primary energy currency of the cell, through oxidative phosphorylation. Efficient energy production is essential for all cellular activities, including the synthesis, breakdown, and transport of lipids. [11] A variant like rs7160151 located near this pseudogene could potentially impact the delicate balance of energy metabolism, which in turn might modulate the availability or utilization of fatty acids such as eicosadienoic acid, thereby contributing to individual differences in metabolic traits and overall lipid profiles. [12]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs7160151 | RPL18P1 - ATP5MC2P2 | eicosadienoic acid measurement |
Definition and Nomenclature of Eicosadienoic Acid
Eicosadienoic acid is precisely defined by its chemical structure, specifically as a fatty acid characterized by a carbon chain length of 20 carbons and two double bonds. This structural characteristic is systematically represented in scientific notation as C20:2, where 'C' denotes carbon, '20' signifies the total number of carbon atoms in the chain, and '2' indicates the number of double bonds present. [2] This standardized nomenclature facilitates clear identification within the extensive array of lipid molecules. However, the precise location of these double bonds along the carbon chain and the specific distribution of carbon atoms in different fatty acid side chains cannot always be definitively determined with standard metabolomics technologies. [2] Furthermore, the process of mapping specific metabolite names to their individual masses can be ambiguous, as stereo-chemical differences or isobaric fragments are not consistently discernible, potentially leading to alternative assignments. [2]
Classification and Biological Context
As a C20:2 fatty acid, eicosadienoic acid is classified within the broad category of lipids, specifically as a long-chain polyunsaturated fatty acid. Fatty acids such as eicosadienoic acid serve as fundamental components for the synthesis of more intricate lipid structures, including phospholipids, which are integral to the architecture and function of cellular membranes. [2] For instance, glycerophospholipids, which encompass glycero-phosphatidylcholines (PC) and glycero-phosphatidylethanolamines (PE), can incorporate such fatty acid side chains, and are further differentiated based on the presence of ester or ether bonds within their glycerol moiety. [2] Analyzing the presence and concentration of specific fatty acids like eicosadienoic acid within serum metabolite profiles offers valuable insights into metabolic traits and potential underlying biological pathways. [8]
Measurement and Analytical Considerations
The quantification of fatty acids, including eicosadienoic acid, within human serum metabolite profiles in research settings typically adheres to standardized measurement protocols. Blood samples are routinely collected following an overnight fasting period to ensure consistent and comparable concentrations of metabolic traits. [8] The concentrations of various lipid components, including fatty acids, are commonly determined using enzymatic methods, often processed by clinical chemistry analyzers. [8] In genome-wide association studies, observed lipid concentrations are frequently adjusted for potential confounding factors such as age, sex, and the use of lipid-lowering therapy. [1] To maintain data integrity and reduce variability, individuals undergoing lipid-lowering treatment or those who have not adhered to fasting requirements are often excluded from these analyses. [8]
Eicosadienoic Acid: An Overview of Structure and Metabolism
Eicosadienoic acid, abbreviated as C20:2, is a fatty acid characterized by a 20-carbon chain containing two double bonds. [2] As a polyunsaturated fatty acid (PUFA), it is a crucial component within the broader class of lipids, which are vital for various biological functions including structural integrity of cell membranes and energy storage. While not explicitly detailed in its direct metabolic fate within the provided context, its classification implies its involvement in the complex network of lipid metabolism, often derived from or converted into other fatty acids. Long-chain polyunsaturated fatty acids, such as eicosadienoic acid, are frequently synthesized in the body from essential fatty acid precursors like linoleic acid. [2]
Genetic Regulation of Fatty Acid Biosynthesis
The synthesis and modification of fatty acids, including eicosadienoic acid, are tightly regulated by genetic mechanisms, notably the fatty acid desaturase (FADS) gene cluster, which includes FADS1 and FADS2. [3] These genes encode enzymes critical for introducing double bonds into fatty acid chains, a process known as desaturation, which is essential for producing various polyunsaturated fatty acids from their precursors. Common genetic variants and haplotypes within the FADS1 FADS2 gene cluster are significantly associated with the fatty acid composition found in phospholipids [3] directly influencing the availability of specific fatty acids like C20:2. Furthermore, single nucleotide polymorphisms (SNPs) within this cluster have been linked to polyunsaturated fatty acid levels in individuals with cardiovascular disease [4] and even to conditions like attention-deficit/hyperactivity disorder [13] highlighting the widespread impact of these genetic regulators on health. Beyond FADS genes, other genetic loci, such as those influencing ANGPTL3 and ANGPTL4 [14], [15] or APOC3 [16] also play critical roles in regulating overall lipid metabolism and concentrations, thereby indirectly affecting the pool of fatty acids like eicosadienoic acid available within the body. [1]
Cellular Pathways and Lipid Homeostasis
Eicosadienoic acid participates in intricate cellular pathways that maintain lipid homeostasis, a balance crucial for cell function and survival. Key enzymes, such as those encoded by the FADS gene cluster, directly catalyze the desaturation steps required for its synthesis and conversion, influencing the fatty acid composition of various complex lipids like phospholipids. [2] These fatty acids serve as integral components of membrane lipid biosynthesis [17] forming the backbone of glycerophospholipids such as phosphatidylcholine, phosphatidylethanolamines, and phosphatidylserines, which are essential for cellular membrane structure and signaling. The regulation of lipid metabolism involves broader networks, including transcription factors like SREBP-2, which links isoprenoid and adenosylcobalamin metabolism [18] further demonstrating the interconnectedness of metabolic pathways. Additionally, enzymes like lipoprotein lipase and hepatic lipase, along with apolipoproteins such as APOA1, APOC3, and APOE, are critical for the processing and transport of lipoproteins, which carry fatty acids and other lipids throughout the body, thereby influencing their cellular uptake and utilization. [19], [20], [21], [22]
Systemic Impact and Pathophysiological Relevance
The systemic balance of fatty acids, including eicosadienoic acid, is intimately linked to various pathophysiological processes, particularly those affecting cardiovascular health. Dysregulation in fatty acid composition, often influenced by genetic variants in genes like the FADS cluster [4] contributes to conditions such as dyslipidemia, characterized by abnormal levels of lipids and lipoproteins in the blood. [11] This imbalance can manifest as hypertriglyceridemia, elevated LDL-cholesterol, or altered HDL-cholesterol levels [1], [19], [23] all of which are established risk factors for coronary artery disease [24] and other cardiovascular diseases. At the organ level, the liver plays a central role in synthesizing, processing, and secreting lipids and lipoproteins, making it a key player in systemic lipid homeostasis. Disruptions in these intricate metabolic pathways, whether due to genetic predispositions or environmental factors, can lead to widespread systemic consequences, impacting not only the cardiovascular system but also potentially contributing to conditions like type 2 diabetes mellitus [1] and even neurodevelopmental disorders. [13]
Fatty Acid Metabolism and Bioavailability
The metabolic fate of fatty acids, including eicosadienoic acid, is intricately linked to both their synthesis and breakdown. Enzymes encoded by the FADS1 and FADS2 gene cluster play a crucial role in the synthesis of long-chain polyunsaturated fatty acids from essential fatty acids like linoleic acid. [3] Genetic variants within this cluster, such as rs174548, are significantly associated with the composition of fatty acids within phospholipids, influencing the balance of various glycerophospholipid species. [2] This suggests a direct impact on the cellular availability and incorporation of specific fatty acids.
Beyond synthesis, the catabolism of fatty acids is initiated by enzymes like short-chain acyl-Coenzyme A dehydrogenase (SCAD) and medium-chain acyl-Coenzyme A dehydrogenase (MCAD), which facilitate beta-oxidation. [2] These enzymes exhibit preferences for different fatty acid chain lengths, and genetic polymorphisms in their respective genes, such as rs2014355 in SCAD and rs11161510 in MCAD, are strongly associated with the ratios of specific acylcarnitines, indicating varying metabolic efficiencies. [2] Fatty acids are transported into mitochondria for beta-oxidation by binding to free carnitine, highlighting the importance of this transport system in energy metabolism. [2]
Regulation of Lipid Homeostasis
The overall balance of lipids and fatty acids, including eicosadienoic acid, is tightly regulated through several key pathways. The mevalonate pathway, critical for cholesterol biosynthesis, is controlled by enzymes like 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR). [25] Common genetic variations affecting HMGCR can influence its alternative splicing, specifically of exon 13, which in turn impacts LDL-cholesterol levels. [26] This enzyme's activity and degradation rate are also modulated by its oligomerization state, demonstrating complex post-translational control. [27]
Further regulation of lipid metabolism involves angiopoietin-like proteins such as ANGPTL3 and ANGPTL4. [14] ANGPTL4, for instance, is identified as a potent factor that can induce hyperlipidemia by inhibiting lipoprotein lipase, an enzyme essential for triglyceride breakdown. [28] Variations in ANGPTL4 are associated with reduced triglycerides and increased high-density lipoprotein (HDL) levels. [15] Additionally, the transcription factor SREBP-2 plays a role in linking isoprenoid metabolism with adenosylcobalamin metabolism, providing another layer of metabolic regulation. [18]
Molecular and Transcriptional Regulatory Mechanisms
The expression and function of enzymes involved in fatty acid pathways are subject to sophisticated molecular regulatory mechanisms. Alternative splicing of pre-mRNA is a significant regulatory process, as demonstrated by the HMGCR gene, where SNPs can affect the splicing pattern of exon 13. [26] This mechanism is also observed with APOB mRNA, where alternative splicing can generate novel protein isoforms, potentially altering lipid transport and metabolism. [29] Such alternative splicing events represent critical control points for gene expression, influencing protein diversity and function. [30]
Beyond splicing, protein modification, such as phosphorylation, can modulate enzyme activity and stability within lipid-related pathways. For example, the phosphorylation of Heat Shock Protein-90 by TSH in thyroid cells illustrates a mechanism by which hormones can exert regulatory control over cellular processes, potentially impacting metabolic states that influence fatty acid handling. [31] Intracellular signaling cascades, including those involving mitogen-activated protein kinase (MAPK) pathways, are also subject to regulation by protein families like tribbles, which suggests a role in coordinating metabolic responses. [32]
Systems-Level Integration and Disease Pathophysiology
The intricate network of fatty acid and lipid pathways is subject to systems-level integration, with pathway crosstalk and hierarchical regulation contributing to emergent biological properties. A genome-wide association network analysis (GWANA) reveals how genes associated with lipid metabolism interact within biological pathways, providing insights into their collective impact on lipid levels. [33] Dysregulation within these interconnected pathways can lead to significant health consequences, such as polygenic dyslipidemia, where common genetic variants at multiple loci contribute to abnormal lipid profiles. [1]
Specific pathway dysregulations are directly implicated in disease-relevant mechanisms. For instance, common genetic variations in fatty acid metabolism are known to moderate the effects of environmental factors, such as breastfeeding, on cognitive development. [34] Alterations in very low-density lipoprotein (VLDL) catabolism, often associated with increased apolipoprotein CIII (APOCIII) and reduced apolipoprotein E (Apo E) on particles, contribute to hypertriglyceridemia. [19] These integrated mechanisms underscore how genetic variations in fatty acid metabolism contribute to complex traits and diseases like coronary artery disease and restless legs syndrome. [7]
References
[1] Kathiresan S, et al. "Common variants at 30 loci contribute to polygenic dyslipidemia." Nat Genet, 2009.
[2] Gieger C, et al. "Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum." PLoS Genet, 2008.
[3] Schaeffer, L. et al. "Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids." Hum Mol Genet, vol. 15, 2006, pp. 1745–1756.
[4] Malerba, G., et al. "SNPs of the FADS Gene Cluster Are Associated with Polyunsaturated Fatty Acids in a Cohort of Patients with Cardiovascular Disease." Lipids, vol. 43, no. 3, 2008, pp. 289–299.
[5] Vasan RS, et al. "Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study." BMC Med Genet, 2007.
[6] Yang, Q. et al. "Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study." BMC Med Genet, vol. 8, suppl. 1, 2007, S9.
[7] Willer, C. J. et al. "Newly identified loci that influence lipid concentrations and risk of coronary artery disease." Nat Genet, vol. 40, no. 2, 2008, pp. 161-169.
[8] Sabatti C, et al. "Genome-wide association analysis of metabolic traits in a birth cohort from a founder population." Nat Genet, 2008.
[9] Sabatti, C. "Genome-wide association analysis of metabolic traits in a birth cohort from a founder population." Nat Genet.
[10] Gieger, C. "Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum." PLoS Genet.
[11] Wallace, C. "Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia." Am J Hum Genet, vol. 82, Jan. 2008, pp. 139–149.
[12] Willer, CJ. "Newly identified loci that influence lipid concentrations and risk of coronary artery disease." Nat Genet.
[13] Brookes, K. J., et al. "Association of Fatty Acid Desaturase Genes with Attention-Deficit/Hyperactivity Disorder." Biological Psychiatry, vol. 60, no. 10, 2006, pp. 1053–1061.
[14] Koishi, R. et al. "Angptl3 regulates lipid metabolism in mice." Nat Genet, vol. 30, 2002, pp. 151–157.
[15] Romeo, S. et al. "Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL." Nat Genet, vol. 39, 2007, pp. 513–516.
[16] Pollin, T. I., et al. "A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection." Science, vol. 322, no. 5904, 2008, pp. 1087–1092.
[17] Vance, J. E. "Membrane Lipid Biosynthesis." Encyclopedia of Life Sciences, John Wiley & Sons, Ltd, Chichester, 2001.
[18] Murphy, C. et al. "Regulation by SREBP-2 defines a potential link between isoprenoid and adenosylcobalamin metabolism." Biochem Biophys Res Commun, vol. 355, 2007, pp. 359–364.
[19] Aalto-Setala, K. et al. "Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles." J. Clin. Invest., vol. 90, 1992, pp. 1889–1900.
[20] Havel, R. J., and J. P. Kane. "Structure and Metabolism of Plasma Lipoproteins." Harrison's Principles of Internal Medicine, 8th ed., McGraw-Hill, New York, 2005, chap. 114.
[21] Isaacs, A., et al. "The -514C->T Hepatic Lipase Promoter Region Polymorphism and Plasma Lipids: A Meta-Analysis." Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 8, 2004, pp. 3858–3863.
[22] Jiang, X. C., et al. "Targeted Mutation of Plasma Phospholipid Transfer Protein Gene Markedly Reduces High-Density Lipoprotein Levels." Journal of Clinical Investigation, vol. 103, no. 7, 1999, pp. 907–914.
[23] Phillipson, B. E., et al. "Reduction of Plasma Lipids, Lipoproteins, and Apoproteins by Dietary Fish Oils in Patients with Hypertriglyceridemia." New England Journal of Medicine, vol. 312, no. 19, 1985, pp. 1210–1216.
[24] Samani, N. J., et al. "Genomewide Association Analysis of Coronary Artery Disease." New England Journal of Medicine, vol. 357, no. 5, 2007, pp. 443–453.
[25] Goldstein, J.L. and Brown, M.S. "Regulation of the mevalonate pathway." Nature, vol. 343, 1990, pp. 425–430.
[26] Burkhardt, R. et al. "Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13." Arterioscler Thromb Vasc Biol, vol. 28, 2008, pp. 2077–2084.
[27] Istvan, E.S. et al. "Crystal structure of the catalytic portion of human HMG-CoA reductase: insights into regulation of activity and catalysis." Embo J, vol. 19, 2000, pp. 819–830.
[28] Yoshida, K. et al. "Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase." J. Lipid Res., vol. 43, 2002, pp. 1770–1772.
[29] Khoo, B. et al. "Antisense oligonucleotide-induced alternative splicing of the APOB mRNA generates a novel isoform of APOB." BMC Mol Biol, vol. 8, 2007, p. 3.
[30] Matlin, A.J. et al. "Understanding alternative splicing: towards a cellular code." Nat Rev Mol Cell Biol, vol. 6, 2005, pp. 386–398.
[31] Ginsberg, J. et al. "Phosphorylation of Heat Shock Protein-90 by TSH in FRTL-5 Thyroid Cells." Thyroid, vol. 16, 2006, pp. 737–742.
[32] Kiss-Toth, E. et al. "Human tribbles, a protein family controlling mitogen-activated protein kinase cascades." J Biol Chem, vol. 279, 2004, pp. 42703–42708.
[33] Aulchenko, Y. S. et al. "Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts." Nat Genet, vol. 41, no. 1, 2009, pp. 47-55.
[34] Caspi, A. et al. "Moderation of breastfeeding effects on the IQ by genetic variation in fatty acid metabolism." Proc Natl Acad Sci U S A, vol. 104, 2007, pp. 18860–18865.